Horm Metab Res 2007; 39(3): 233-235
DOI: 10.1055/s-2007-970425
Short Communication

© Georg Thieme Verlag KG Stuttgart · New York

Pigment Epithelium-derived Factor (PEDF) Blocks Advanced Glycation End Product (AGE)-induced Angiogenesis In Vitro

S.-I. Yamagishi 1 , K. Nakamura 1 , T. Matsui 1 , T. Yoshida 1 , M. Takeuchi 2 , T. Imaizumi 1
  • 1Departments of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
  • 2Department of Pathophysiological Science, Faculty of Pharmaceutical Science, Hokuriku University, Kanazawa, Japan
Further Information

Publication History

received 22. 5. 2006

accepted 11. 9. 2006

Publication Date:
20 March 2007 (online)

Introduction

Pigment epithelium-derived factor (PEDF) was first purified from the conditioned media of human retinal pigment epithelial cells with neuronal differentiating activity [1]. Recently, PEDF has been shown to be the most potent inhibitor of angiogenesis in the mammalian eye; it suppressed ischemia-induced retinal neovascularization [1]. These observations suggest that PEDF could protect against angiogenic eye disease such as proliferative diabetic retinopathy.

We, along with others, have shown that advanced glycation end products (AGEs), the senescent macroprotein derivatives, whose formation and accumulation occur at an accelerated rate in diabetes, are implicated in the development and progression of diabetic retinopathy as well [2] [3]. Indeed, AGEs could stimulate angiogenesis of cultured microvascular endothelial cells (ECs) by inducing autocrine production of vascular endothelial growth factor (VEGF), a key mediator of diabetic retinopathy [4]. In this study, we have investigated whether PEDF could inhibit the AGE-induced angiogenesis in vitro.

References

  • 1 Tombran-Tink J, Barnstable CJ. Nat Rev Neurosci. 2003;  4 628-636
  • 2 Yamagishi S, Imaizumi T. Curr Pharm Des. 2005;  11 2279-2299
  • 3 Stitt AW, Frizzell N, Thorpe SR. Curr Pharm Des. 2004;  10 3349-3360
  • 4 Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z. FASEB J. 2002;  16 1928-1930
  • 5 Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M, Makita Z. Biochem Biophys Res Commun. 2002;  296 877-882
  • 6 Takeuchi M, Watai T, Sasaki N, Choei H, Iwaki M, Ashizawa T, Inagaki Y, Yamagishi S, Kikuchi S, Riederer P, Saito T, Bucala R, Kameda Y. J Neuropathol Exp Neurol. 2003;  62 486-496
  • 7 Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Makita Z. J Biol Chem. 2002;  277 20309-20315
  • 8 Yokoi M, Yamagishi SI, Takeuchi M, Ohgami K, Okamoto T, Saito W, Muramatsu M, Imaizumi T, Ohno S. Br J Ophthalmol. 2005;  89 673-675
  • 9 Spranger J, Osterhoff M, Reimann M, Möhlig M, Ristow M, Francis MK, Cristofalo V, Hammes HP, Smith G, Boulton M, Pfeiffer AF. Diabetes. 2001;  50 2641-2645
  • 10 Boehm BO, Lang G, Volpert O, Jehle PM, Kurkhaus A, Rosinger S, Lang GK, Bouck N. Diabetologia. 2003;  46 394-400

Correspondence

S.-I. Yamagishi

Department of Internal Medicine · Kurume University School of Medicine

67 Asahi-machi

Kurume 830-0011

Japan

Phone: +81/942/31 75 80

Fax: +81/942/31 77 07

Email: shoichi@med.kurume-u.ac.jp

    >